Wenhuo Hu
About Wenhuo Hu
Wenhuo Hu is a Principle Scientist at Bristol Myers Squibb in Redwood City, California, with a background in molecular genetics and community health.
Current Role at Bristol Myers Squibb
Wenhuo Hu is currently serving as a Principle Scientist at Bristol Myers Squibb, located in Redwood City, California, United States. His role involves leading scientific research and projects within the company. The position reflects his extensive expertise and experience in the field of molecular genetics and cancer research.
Previous Experience at Memorial Sloan Kettering Cancer Center
Before joining Bristol Myers Squibb, Wenhuo Hu worked at Memorial Sloan Kettering Cancer Center as a Senior Research Scientist. He served in this role from 2010 to 2021, contributing to various research initiatives aimed at understanding and combating cancer. This decade-long tenure highlights his commitment and substantial contributions to cancer research.
Early Career at Center of Disease Control, Ningbo City
Wenhuo Hu began his career as a Preventive Doctor at the Center of Disease Control in Zhenhai district, Ningbo City, China. He worked in this capacity from 1999 to 2003. His responsibilities included preventive healthcare measures and public health initiatives. This role laid the foundation for his subsequent transition into advanced scientific research.
Educational Background in Health and Genetics
Wenhuo Hu's academic journey began with a Doctor of Medicine (M.D.) in Community Health and Preventive Medicine from Zhejiang University, completed in 1999. He further advanced his education by obtaining a Doctor of Philosophy (Ph.D.) in Molecular Genetics from the Graduate University Chinese Academy of Sciences in 2009. These educational achievements have provided him with a strong foundation in both medical practice and genetic research.
Research Contributions to Bladder Cancer Studies
Wenhuo Hu has made significant contributions to research on bladder cancer as the sole data analyst on the P01 grant P01-CA221757. His involvement spans multiple projects under this grant, including Project 1, which investigates the role of the H3K27 demethylase KDM6A, Project 2, which examines the functions of ARID1A in muscle invasive bladder cancer, and Project 3, focusing on tumor evolution and drug response in bladder cancer organoids. His work has been pivotal in advancing the understanding of bladder cancer pathogenesis and treatment.